Lipid-metabolism-focused CRISPR screens identify enzymes of the mevalonate pathway as essential for prostate cancer growth
Cell Reports · 2025
DOI: 10.1016/j.celrep.2025.115470 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Gio Fidelito und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Physiology, The University of Melbourne, Parkville, VIC 3010, Australia. Hauptthemen laut MEDLINE: Mevalonic Acid, Prostatic Neoplasms, Lipid Metabolism, CRISPR-Cas Systems. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prostate Cancer Foundation of Australia, Victorian Cancer Agency, National Health and Medical Research Council.
Abstract (Originalsprache)
Dysregulated lipid metabolism plays an important role in prostate cancer, although the understanding of the essential regulatory processes in tumorigenesis is incomplete. We employ a CRISPR-Cas9 screen using a custom human lipid metabolism knockout library to identify essential genes for prostate cancer survival. Screening in three prostate cancer cell lines reveals 63 shared dependencies, with enrichment in terpenoid backbone synthesis and N-glycan biosynthesis. Independent knockout of key genes of the mevalonate pathway reduces cell proliferation. Further investigation focuses on NUS1, a subunit of cis-prenyltransferase required for dolichol synthesis. NUS1 knockout decreases tumor growth in vivo and viability in patient-derived xenograft (PDX)-derived organoids. Mechanistic studies reveal that loss of NUS1 promotes oxidative stress, lipid peroxidation and ferroptosis sensitivity, endoplasmic reticulum (ER) stress, and G1 cell-cycle arrest, and it dampens androgen receptor (AR) signaling, collectively leading to growth arrest. This study highlights the critical role of the mevalonate-dolichol-N-glycan biosynthesis pathway, particularly NUS1, in prostate cancer survival and growth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy and Physiology, The University of Melbourne, Parkville, VIC 3010, Australia.
- Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
- Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; The Walter and Eliza Hall…
- Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Department of Physiology,…
- Department of Anatomy and Physiology, The University of Melbourne, Parkville, VIC 3010, Australia. Electronic address: matt.watt@unimelb.edu.au.
Förderung
- Prostate Cancer Foundation of Australia
- Victorian Cancer Agency
- National Health and Medical Research Council
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- CSL Limited
- Cancer Council Victoria
- Diabetes Australia Research Trust
- University of Melbourne
Zitieren
APA
Fidelito, G., Todorovski, I., Cluse, L., Vervoort, S. J., Taylor, R. A., & Watt, M. J. (2025). Lipid-metabolism-focused CRISPR screens identify enzymes of the mevalonate pathway as essential for prostate cancer growth. Cell Reports. https://doi.org/10.1016/j.celrep.2025.115470
Vancouver
Fidelito G, Todorovski I, Cluse L, Vervoort SJ, Taylor RA, Watt MJ. Lipid-metabolism-focused CRISPR screens identify enzymes of the mevalonate pathway as essential for prostate cancer growth. Cell Reports. 2025. doi:10.1016/j.celrep.2025.115470
BibTeX
@article{Fidelito2025,
author = {Fidelito, Gio and Todorovski, Izabela and Cluse, Leonie and Vervoort, Stephin J and Taylor, Renea A and Watt, Matthew J},
title = {Lipid-metabolism-focused CRISPR screens identify enzymes of the mevalonate pathway as essential for prostate cancer growth},
journal = {Cell Reports},
year = {2025},
doi = {10.1016/j.celrep.2025.115470}
}
EUVIMED